What are the current hypertension management guidelines for adults, including diagnostic thresholds, lifestyle recommendations, first‑line drug classes, target blood pressure goals, and special considerations for patients with diabetes, chronic kidney disease (CKD), cardiovascular disease (CVD), or those aged ≥ 65 years?

Current Hypertension Management Guidelines

The 2024 ESC guidelines recommend treating most adults with confirmed hypertension (BP ≥140/90 mmHg) to a target systolic BP of 120–129 mmHg using initial combination therapy with a RAS blocker (ACE inhibitor or ARB) plus either a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic, preferably as a single-pill combination. 1

Diagnostic Thresholds

Office BP measurement:

• Hypertension is diagnosed at ≥140/90 mmHg based on repeated office measurements (average of 2–3 readings over 2–3 visits) 1
• Confirm with home BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg 1
• Use validated automated upper arm cuff devices with appropriate cuff size 1
• Measure BP in both arms simultaneously at first visit; use the arm with higher readings for subsequent measurements 1

BP categories:

• Normal: <130/85 mmHg (remeasure after 3 years) 1
• High-normal/Elevated: 130–139/85–89 mmHg 1
• Grade 1 Hypertension: 140–159/90–99 mmHg 1
• Grade 2 Hypertension: ≥160/100 mmHg 1

Treatment Initiation Strategy

Immediate pharmacological treatment is indicated for:

• All patients with BP ≥140/90 mmHg regardless of cardiovascular risk 1
• High-risk patients (CVD, CKD, diabetes, organ damage, or aged 50–80 years) with Grade 1 hypertension 1
• Grade 2 hypertension (≥160/100 mmHg) in all patients 1

Delayed treatment (after 3–6 months of lifestyle intervention):

• Low-to-moderate risk patients with Grade 1 hypertension (140–159/90–99 mmHg) 1
• Adults with elevated BP (130–139/80–89 mmHg) and high CVD risk (≥10% over 10 years) who remain ≥130/80 mmHg after 3 months of lifestyle measures 1

Lifestyle Recommendations

All patients with hypertension or elevated BP should receive:

• Dietary sodium restriction and DASH-style eating pattern 1
• Regular physical activity 1
• Weight management if overweight/obese 1
• Smoking cessation 2
• Alcohol moderation 1

First-Line Drug Classes

Initial combination therapy is recommended for most patients with confirmed hypertension (BP ≥140/90 mmHg) 1:

Non-Black patients:

1. RAS blocker (ACE inhibitor or ARB) + dihydropyridine CCB, OR
2. RAS blocker + thiazide/thiazide-like diuretic 1

Black patients:

1. ARB + dihydropyridine CCB, OR
2. Dihydropyridine CCB + thiazide/thiazide-like diuretic 1

Monotherapy exceptions:

• Patients aged >80 years or frail 1
• Low-risk Grade 1 hypertension 1
• Symptomatic orthostatic hypotension 1
• Moderate-to-severe frailty 1

Fixed-dose single-pill combinations are strongly recommended to improve adherence 1

Treatment Escalation Algorithm

Step 1: Low-dose RAS blocker + CCB or diuretic (single-pill combination preferred) 1

Step 2: Increase to full dose of combination 1

Step 3: Triple therapy—RAS blocker + dihydropyridine CCB + thiazide/thiazide-like diuretic (single-pill combination preferred) 1

Step 4: Add spironolactone; if not tolerated or contraindicated, use amiloride, doxazosin, eplerenone, clonidine, or beta-blocker 1

Step 5: Refer to hypertension specialist if BP remains uncontrolled 1

Critical caveat: Never combine ACE inhibitor with ARB—this is contraindicated 1

Blood Pressure Target Goals

General population:

• Target systolic BP 120–129 mmHg if treatment is well tolerated 1
• This represents a significant shift from older guidelines that targeted <140/90 mmHg 1
• If poorly tolerated, use "as low as reasonably achievable" (ALARA) principle 1
• Achieve target within 3 months of initiating therapy 1

Alternative guideline thresholds:

• The 2020 ISH guidelines recommend targeting <130/80 mmHg for most adults, with initial target <140/90 mmHg 1
• The 2017 ACC/AHA guidelines recommend <130/80 mmHg for all adults 1

Special Population Considerations

Diabetes

• Initiate treatment immediately when BP ≥140/90 mmHg 1, 2
• Target BP <130/80 mmHg 2
• First-line agents: ACE inhibitor or ARB (for renoprotection), combined with CCB or thiazide diuretic 3, 2
• Use home and ambulatory BP monitoring to detect masked or nocturnal hypertension 2

Chronic Kidney Disease (CKD)

• Initiate treatment immediately when BP ≥140/90 mmHg 1
• Target systolic BP 120–129 mmHg (ESC 2024) or <130/80 mmHg (other guidelines) 1, 3
• First-line agent: ACE inhibitor or ARB for albuminuria and kidney protection 4, 3
• Continue RAS inhibitors even when eGFR falls below 45 mL/min/1.73 m²—discontinuation increases risk of ESRD, cardiovascular events, and mortality 5
• Add dihydropyridine CCB (never as monotherapy in proteinuric CKD) or thiazide-like diuretic 3
• Non-dihydropyridine CCBs reduce albuminuria and slow kidney function decline 3

Cardiovascular Disease (CVD)

• Initiate treatment immediately when BP ≥140/90 mmHg 1
• Target systolic BP 120–129 mmHg 1
• Beta-blockers are indicated for specific cardiac conditions: angina, post-MI, heart failure with reduced ejection fraction, or heart rate control 1
• Thiazide-type diuretics (especially chlorthalidone) superior to CCBs and ACE inhibitors for preventing heart failure 1

Elderly (≥65 years)

• Continue treatment beyond age 85 if well tolerated 1
• Target systolic BP 120–129 mmHg if tolerated, but individualize based on frailty 1
• For frail or very elderly (>80 years), consider monotherapy initially 1
• Avoid targeting systolic BP <120 mmHg 1
• Monitor closely for hypotension, falls, and adverse effects 1
• The 2013 JNC 8 guideline recommended <150/90 mmHg for adults ≥60 years, but newer guidelines favor lower targets 4

Pregnancy

• Initiate treatment when BP ≥140/90 mmHg (both gestational and chronic hypertension) 1
• Target BP <140/90 mmHg but not <80 mmHg diastolic 1
• First-line agents: Extended-release nifedipine (dihydropyridine CCB), labetalol, or methyldopa 1
• Avoid ACE inhibitors and ARBs—teratogenic 1

Young Adults (<40 years)

• Comprehensive screening for secondary hypertension is mandatory, except in obese young adults where obstructive sleep apnea evaluation should be prioritized 1

Monitoring and Follow-Up

Initial phase:

• Follow-up within 1–2 months after initiating therapy 1
• Achieve BP control within 3 months 1

Maintenance phase:

• After achieving target: follow-up every 3–6 months 1
• Reassess cardiovascular risk factors and organ damage every 2 years 1

Medication timing:

• Take medications at the most convenient time to establish habitual pattern and improve adherence 1
• No specific evidence mandating morning versus evening dosing for most patients 1

Common Pitfalls and Caveats

Avoid these errors:

• Never combine ACE inhibitor with ARB—increases adverse events without additional benefit 1
• Never use dihydropyridine CCB as monotherapy in proteinuric CKD—always combine with RAS blocker 3
• Do not discontinue RAS inhibitors when eGFR falls below 45 mL/min/1.73 m²—continuation reduces ESRD and cardiovascular events 5
• Do not use beta-blockers as first-line monotherapy unless specific cardiac indication exists—less effective for stroke prevention 1
• Do not use alpha-blockers as first-line therapy—less effective than other agents for CVD prevention 1

Key considerations:

• ACE inhibitors are less effective than thiazide diuretics and CCBs in black patients for stroke and heart failure prevention 1
• Chlorthalidone (thiazide-type diuretic) superior to amlodipine and lisinopril for preventing heart failure 1
• Single-pill combinations dramatically improve adherence and should be used whenever possible 1
• Check medication adherence before escalating therapy or diagnosing resistant hypertension 1